<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475148</url>
  </required_header>
  <id_info>
    <org_study_id>CR107482</org_study_id>
    <secondary_id>2015-000942-53</secondary_id>
    <secondary_id>54175446EDI1001</secondary_id>
    <nct_id>NCT02475148</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag International NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag International NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of JNJ-54175446&#xD;
      versus placebo after single oral dose administration (ascending dose levels), to determine&#xD;
      the maximal tolerated dose (MTD) or the safety and tolerability at exposures resulting in&#xD;
      full target engagement for at least 24 hours in all participants (whichever comes first), to&#xD;
      characterize the pharmacokinetics of JNJ-54175446 in plasma, cerebrospinal fluid (CSF) and&#xD;
      urine and to investigate the effect of food (high fat/high calorie) on the pharmacokinetics&#xD;
      of JNJ 54175446 after single oral dose administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, single ascending dose study in&#xD;
      healthy participants for JNJ-54175446. The study will consist of 3 phases: a screening phase&#xD;
      (between 21 and 2 days prior to dose administration), a double-blind treatment phase (8 days;&#xD;
      Part 1 and Part 3) or an open-label treatment phase (8 days; Part 2), and a follow-up&#xD;
      examination (within 14 to 21 days after dose administration). The maximal study duration for&#xD;
      a participant will not exceed 6 weeks. In each cohort of Part 1 (6 cohorts) and Part 3 (1&#xD;
      cohort), participants will be randomly assigned to receive JNJ-54175446 or matching placebo&#xD;
      and in cohort of part 2, all participants will be assigned to JNJ-54175446 treatment. In part&#xD;
      1, primarily maximum tolerated dose (MTD) will be assessed, along with safety and&#xD;
      tolerability of JNJ-54175446. In part 2, pharmacokinetics (PK) of JNJ-54175446 in&#xD;
      cerebrospinal fluid (CSF) will be assessed. In part 3, the effect of food on the plasma PK of&#xD;
      JNJ-54175446 in young healthy male participants will be assessed. Safety will be monitored&#xD;
      throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Baseline up to 14 or 21 days after study drug administration</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of JNJ-54175446 in Part 1</measure>
    <time_frame>Baseline up to 24 Hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma and Cerebrospinal Fluid (CSF) Concentration (Cmax)</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
    <description>The Cmax is the maximum observed concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Last Quantifiable Plasma and Cerebrospinal Fluid (CSF) Concentration (Clast)</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma and Cerebrospinal Fluid Concentration (Tmax)</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Last Quantifiable Plasma and Cerebrospinal Fluid Concentration (Tlast)</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve From Time of Administration up to the Last Time Point with a Measurable Plasma and Cerebrospinal Fluid Concentration (AUClast)</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma and Cerebrospinal Fluid Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>First-order Rate Constant (Lambda[z])</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-Life (t1/2)</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
    <description>The elimination half-life (t1/2) is the time measured for the plasma/CSF concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Clearance (CL/F)</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
    <description>Total clearance of drug after extravascular administration, uncorrected for absolute bioavailability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine Clearance</measure>
    <time_frame>Pre-dose; 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, 120, 144 hours after study drug administration</time_frame>
    <description>Creatinine clearance was calculated by Cockroft-Gault formula. Creatinine clearance is equal to 140 minus age multiplied by weight and constant (1 for men and 0.85 for women) divided by creatinine in (micro mole per liter).</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-54175446 0.5 milligram (mg) or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-54175446 2.5 mg or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-54175446 10 mg or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-54175446 30 mg or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-54175446 100 mg or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-54175446 200 mg or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-54175446 on Day 1 along with high fat/high calorie breakfast. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ 54175446</intervention_name>
    <arm_group_label>Part 1: Cohort 1</arm_group_label>
    <arm_group_label>Part 1: Cohort 2</arm_group_label>
    <arm_group_label>Part 1: Cohort 3</arm_group_label>
    <arm_group_label>Part 1: Cohort 4</arm_group_label>
    <arm_group_label>Part 1: Cohort 5</arm_group_label>
    <arm_group_label>Part 1: Cohort 6</arm_group_label>
    <arm_group_label>Part 2: Cohort 7</arm_group_label>
    <arm_group_label>Part 3: Cohort 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part 1: Cohort 1</arm_group_label>
    <arm_group_label>Part 1: Cohort 2</arm_group_label>
    <arm_group_label>Part 1: Cohort 3</arm_group_label>
    <arm_group_label>Part 1: Cohort 4</arm_group_label>
    <arm_group_label>Part 1: Cohort 5</arm_group_label>
    <arm_group_label>Part 1: Cohort 6</arm_group_label>
    <arm_group_label>Part 3: Cohort 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High fat/high Calorie Breakfast</intervention_name>
    <arm_group_label>Part 3: Cohort 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have a body mass index (BMI) between 18 and 32 kg/m^2, inclusive&#xD;
             (BMI = weight/height^2)&#xD;
&#xD;
          -  Participants must be healthy on the basis of clinical laboratory tests performed at&#xD;
             screening. If the results of the serum chemistry panel[excluding liver function&#xD;
             tests], hematology, or urinalysis are outside the normal reference ranges, the&#xD;
             participant may be included only if the investigator judges the abnormalities to be&#xD;
             not clinically significant. This determination must be recorded in the subject's&#xD;
             source documents and initialed by the investigator&#xD;
&#xD;
          -  A man who is sexually active with a woman of childbearing potential and has not had a&#xD;
             vasectomy must agree to use a barrier method of birth control e.g., either condom with&#xD;
             spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm&#xD;
             or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men&#xD;
             must also not donate sperm during the study and for 3 months after receiving the last&#xD;
             dose of study drug. In addition, their female partner should also use an appropriate&#xD;
             method of birth control for at least the same duration&#xD;
&#xD;
        For Part 1 and 3:&#xD;
&#xD;
        - Healthy male participants between 18 and 54 years of age, inclusive&#xD;
&#xD;
        For Part 2:&#xD;
&#xD;
          -  Healthy male or female participants between 55 and 75 years of age, inclusive&#xD;
&#xD;
          -  Participant must be healthy on the basis of both physical and neurological examination&#xD;
             performed at screening and at admission to the clinical unit&#xD;
&#xD;
          -  Women must not be of childbearing potential (i.e., must be postmenopausal with&#xD;
             amenorrhea for at least 12 months); permanently sterilized (e.g., tubal occlusion,&#xD;
             hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a history of or current liver or renal insufficiency; significant&#xD;
             cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic&#xD;
             (including coagulation disorders), rheumatologic, psychiatric, or metabolic&#xD;
             disturbances, any inflammatory illness or any other illness that the Investigator&#xD;
             considers should exclude the participant&#xD;
&#xD;
          -  Participant has any liver function test (including alanine aminotransferase [ALT],&#xD;
             aspartate aminotransferase [AST], gamma-glutamyltransferase [gamma-GT], alkaline&#xD;
             phosphatase [ALP] and bilirubin) at screening exceeding the upper limit of normal&#xD;
&#xD;
          -  Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C&#xD;
             antibody (anti-HCV) positive, or other clinically active liver disease, or tests&#xD;
             positive for HBsAg or anti-HCV at Screening&#xD;
&#xD;
          -  Participant has a history of human immunodeficiency virus (HIV) antibody positive, or&#xD;
             tests positive for HIV at Screening&#xD;
&#xD;
          -  Participant has a Prothrombin time [PT] &gt;14 seconds and/or an activated partial&#xD;
             thromboplastin time [aPTT] &gt;35 seconds&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag International NV Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag International NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JNJ-54175446</keyword>
  <keyword>Healthy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

